Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment
- PMID: 574098
Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment
Abstract
Blood glucose, lipoproteins, non-esterified fatty acids, fibrinogen and intermediary metabolites were measured in twenty-two diet failed maturity onset diabetics during a double blind crossover study of metformin (1.7 g/day) or clofibrate (2 g/day) therapy. Patients received combined therapy for a final two month period. Four patients had 12 hour metabolic profiles performed during each treatment period. A more significant improvement in fasting blood glucose and glycosuria occured with metformin and combined therapy. However, clofibrate and combined therapy significantly decreased total and low density lipoprotein cholesterol, total and very low density lipoprotein triglyceride and fibrinogen. Metabolic profiles demonstrated significant elevations of blood lactate and alanine with metformin treatment but these parameters returned to normal with combined therapy. Non-esterified fatty acids and glycerol were significantly lower during combined therapy compared with metformin or clofibrate alone. Despite the recent adverse report on clofibrate, this study indicates that the addition of clofibrate to metformin therapy may have advantages in the management of maturity onset diabetics.
Similar articles
-
Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetice.Horm Metab Res. 1979 May;11(5):332-7. doi: 10.1055/s-0028-1092733. Horm Metab Res. 1979. PMID: 573232
-
Comparative effects of two doses of glibenclamide upon metabolic rhythms in maturity-onset diabetics.Diabete Metab. 1978 Sep;4(3):175-80. Diabete Metab. 1978. PMID: 101402
-
The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).Diabete Metab. 1991 May;17(1 Pt 2):197-200. Diabete Metab. 1991. PMID: 1936476 Clinical Trial.
-
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.Am J Med. 2008 Feb;121(2):149-157.e2. doi: 10.1016/j.amjmed.2007.09.016. Am J Med. 2008. PMID: 18261504 Review.
-
Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.Pharmacotherapy. 1995 May-Jun;15(3):317-37. Pharmacotherapy. 1995. PMID: 7667166 Review.
Cited by
-
Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes.NPJ Syst Biol Appl. 2023 May 23;9(1):18. doi: 10.1038/s41540-023-00275-8. NPJ Syst Biol Appl. 2023. PMID: 37221264 Free PMC article.
-
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Cochrane Database Syst Rev. 2010. PMID: 20393934 Free PMC article.
-
Lactate Levels with Chronic Metformin Use: A Narrative Review.Clin Drug Investig. 2017 Nov;37(11):991-1007. doi: 10.1007/s40261-017-0564-6. Clin Drug Investig. 2017. PMID: 28836132 Review.
-
Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations.Acta Diabetol Lat. 1990 Apr-Jun;27(2):139-55. doi: 10.1007/BF02581286. Acta Diabetol Lat. 1990. PMID: 2198745
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources